Medpace Holdings Inc vs United Microelectronics Corp — how do they compare? Medpace Holdings Inc trades at $617.76 (market cap $16.82B), while United Microelectronics Corp trades at $22.97 (market cap $58.02B). The key difference: United Microelectronics Corp is far larger — about 3.4× Medpace Holdings Inc's market cap, and United Microelectronics Corp pays a 1.76% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and United Microelectronics Corp for 42 Days on average.
| MEDP | UMC | |
|---|---|---|
Market Cap | $16.82B | $58.02B |
Volume | 223,093 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $630.19 | $28.02 |
52-Week Low | $393.42 | $7.02 |
Typical Hold Time | 14 Days | 42 Days |
Enterprise Value | $16.44B | $55.10B |
Dividend Yield | — | 1.76% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
UMC trades at $22.92, down 1.67% on the day, with a bullish technical signal despite recent weakness. The company has delivered strong earnings beats in recent quarters, with Q2 2026 EPS of $0.54 significantly exceeding the $0.16 estimate. Revenue is projected to grow to $250.7 billion in 2026, with net income margin improving to 32.75%. Cash flow trends show a positive turnaround with 2025 net cash flow of $5.66 billion after two years of negative flows.
The outlook remains positive with strong profitability metrics and analyst upgrades, though competition and market volatility present risks. The stock appears fundamentally sound with improving cash generation and earnings momentum, supported by AI-driven semiconductor demand. Valuation metrics suggest reasonable pricing relative to growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →